CreatorsPublishersAdvertisers
View more in
Science

Ruxolitinib Represents a Key Clinical Tool in Polycythemia Vera Paradigm

onclive.com
 2021-09-11

The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea. The JAK1/JAK2 inhibitor ruxolitinib (Jakafi) has several clinical uses in the treatment of patients with polycythemia

www.onclive.com

Comments / 0

Comments / 0